post-stroke cognitive impairment
Conditions
Interventions
The combination therapy group:None
The citicoline sodium monotherapy group:None
The idebenone monotherapy group:None
The GM-1 monotherapy group:None
Sponsors
Shaanxi Triffic Hospital
Eligibility
Sex/Gender
All
Age
30 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Age 30-85 years old (including 30 and 85 years old), any gender; 2. Diagnosed with ischemic stroke (NIHSS=18) due to cerebral infarction by computed tomography or magnetic resonance imaging within 1 week of onset and meeting the 2018 Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke; 3. Presence of acute cognitive impairment after stroke (MoCA score < 25); 4. Not previously treated with GM1, Cerebrolysin, or edaravone; 5. Patients are conscious and able to cooperate with examinations, questionnaires, and medical history collection independently or with the help of family members; 6. Willing to participate in this study.
Exclusion criteria
Exclusion criteria: 1. Non-first-ever ischemic stroke, non-cortical infarction, hemorrhagic stroke, stroke due to trauma or traumatic surgery; 2. History of head injury, epilepsy, severe depression, anxiety, or other conditions that may affect cognitive function; 3. History of non-sinus cardiac arrhythmia (such as atrial fibrillation, atrial flutter, rhythmic arrhythmia, or other arrhythmias), myocardial infarction, heart failure, or implanted pacemaker, as well as severe lung, liver, kidney diseases, or malignant tumors which may significantly impact the experimental results; 4. Inability to complete neuropsychological tests due to mental abnormalities, severe aphasia, sensory or motor functional impairments, or consciousness disorders affecting written and verbal expression; 5. Suffering from chronic debilitating diseases or tumors, such as gastrointestinal ulcers, inflammatory bowel disease, or severe liver diseases; 6. Allergic to investigational samples or intolerant due to significant gastrointestinal symptoms; 7.Patients with irregular or significantly fluctuating dietary habits during the follow-up period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in MMSE scores compared to the baseline; | — |
Secondary
| Measure | Time frame |
|---|---|
| The change in MoCA scores compared to the baseline;The change in ADL scores compared to the baseline;The change in MMSE scores compared to the baseline;The change in MoCA scores compared to the baseline;The change in ADL scores compared to the baseline;The variation of MMSE scores among different medication regimens;The variation of MoCA scores among different medication regimens;The variation of ADL scores among different medication regimens; | — |
Countries
China
Contacts
Public ContactZhang Hengqiang
Shaanxi Triffic Hospital
Outcome results
None listed